Amifostine in reducing cisplatin toxicity.
Amifostine has been demonstrated in preclinical evaluation and through the conduct of a randomized controlled clinical trial to reduce the incidence and severity of cisplatin-associated toxicity. While the role of amifostine in standard oncologic management remains to be defined, patients who require treatment with cisplatin who have preexisting renal or neurologic dysfunction may have their potential for further damage to these organs reduced if amifostine is delivered along with the cytotoxic drug.
Markman
M
M
The Cleveland Clinic Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005544:Forecasting; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D004999:Amifostine; D002945:Cisplatin